Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) said on Thursday that it has launched its butalbital acetaminophen and caffeine (BAC) capsule in 50mg/300mg/40mg in the United States for the treatment of tension headache (migraine).
It comes after the company received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for BAC.
US sales of BAC capsule 50mg/300mg/40mg were approximately USD40m for the 12 months ending 31 March 2020, according to IQVIA.
Mayne Pharma markets more than 60 generic and specialty branded pharmaceuticals in the US.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial